We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals

Delisted

EIGR was delisted on the 10th of April, 2024.

45 hedge funds and large institutions have $64.3M invested in Eiger BioPharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 3

83% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 6

71% more capital inflows, than outflows

Capital inflows: $9.6M | Capital outflows: $5.64M

50% more funds holding

Funds holding: 30 → 45 (+15)

1.79% more ownership

Funds ownership: 42.66% → 44.45% (+1.8%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
45
Holders Change
+15
Holders Change %
+50%
% of All Funds
1.2%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
18
Increased
11
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

EIGR Hedge Fund Activity: Q2 2016 in Review

45 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals (EIGR) for Q2 2016, worth a combined $64.3M — up 26% from $51.1M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new EIGR positions and 3 closed out — a net gain of 15 holders — while 11 added to existing stakes and 6 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $2M. The largest seller was EcoR1 Capital, cutting an estimated $3.55M.

  • 45 institutional investors held Eiger BioPharmaceuticals (EIGR) as of Q2 2016, up from 30 in Q1 2016.
  • Funds reported $64.3M of Eiger BioPharmaceuticals stock for Q2 2016, up 26% quarter-over-quarter.
  • 18 funds opened new Eiger BioPharmaceuticals positions in Q2 2016 and 3 closed out, a net change of +15 holders.
  • The largest Eiger BioPharmaceuticals buyer in Q2 2016 was Wellington Management Group, an estimated $2M added.
  • The largest Eiger BioPharmaceuticals seller in Q2 2016 was EcoR1 Capital, an estimated $3.55M sold.

Based on aggregated 13F filings for Q2 2016.